Clinical Trial

Lorraine Registry of Multiple Sclerosis

Study acronym: RelSEP
Recruiting
View on ClinicalTrials.gov →
Summary
The RelSEP aims to register exhaustively every new case of multiple sclerosis (MS) occuring in Lorraine a French region, and follow up on them for an indefinite duration, registering disease evolution and intercurrent events.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2016-08-25; most recent amendment 2023-02-06.
Trial Details
NCT Number NCT02883335
Lead Sponsor Central Hospital, Nancy, France
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, University of Lorraine
Conditions Multiple Sclerosis
Enrollment 6,000 participants
Start Date 2003-05
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2023-02-08